Donate For Public and Patients Store Search

S029 - Controversies and Difficult Questions Concerning Biologic Therapeutics

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Analyze currently available drug choices for adult and children with relatively severe psoriasis.
  • Analyze currently available drug choices for adults and children with relatively severe atopic dermatitis
  • Recognize future biologics and small molecules on the horizon for a wide variety of important dermatoses.

Description

There are rapidly expanding choices for biologics in a variety of important dermatoses. Areas of emphasis will include (a) pediatric psoriasis and atopic dermatitis drug choices, (b) adult psoriasis current biologics choices versus new drugs on the horizon, (c) small molecules with similar efficacy to biologics in psoriasis, (d) refining rituximab role in pemphigus, (e) and sorting out why biologics commonly lose efficacy over time. There is seldom a single "correct" answer, yet patients expect clinicians to make the best decision with currently available data. The speakers will strive to provide the most current data for these issues.

Disclosures

  • Armstrong, April W., MD, MPH: AbbVie – A(H), C(H), Data Safety Monitoring Board(H), I(Grants/Research Funding), SP(H); Amgen – A(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Demira – I(Grants/Research Funding); Dermavant Sciences – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – C(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), SP(H); Janssen-Ortho Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Merck & Co., Inc – A(H); Modernizing Medicine – C(H); NIH – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Parexel – Data Safety Monitoring Board(H); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H);
  • Cordoro, Kelly M., MD: Celgene Corporation – C(Fees);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Tomayko, Mary M., MD, PhD: no financial relationships exist with commercial interests.
  • Wolverton, Stephen E., MD: Elsevier Inc. – Independent Contractor(OB);
  • Wu, Jashin J., MD: C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene – C(H), SP(H); Demira – C(H); Dr Reddy's Laboratory – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(H); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Promius Pharma, LLC – C(H); Regeneron – C(H), SP(H); Sanofi Genzyme – SP(H); Sun Pharmaceutical Industries Ltd. – C(H), SP(H); UCB – C(H), SP(H); Valeant Pharmaceuticals North America LLC – C(H), SP(H);
Schedule
Saturday, March 2
1:00 PM
Dr. Gordon / To treat to target or not in psoriasis
1:30 PM
Dr. Wu / With multiple recent biologics for psoriasis, is there any room for Tyk2 inhibitors?
2:00 PM
Dr. Wolverton / Some reasons which biologics lose efficacy over time in the real world
2:30 PM
Dr. Armstrong / New biologics on the horizon for a variety of important dermatoses
3:00 PM
Dr. Cordoro / Between a rock and a hard place; pediatric management dilemmas
3:30 PM
Dr. Tomayko / Rituximab mechanisms for pemphigus: beyond CD20 effects
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Salon I
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Stephen E. Wolverton, MD, FAAD
Speakers
  • April W. Armstrong, MD, MPH, FAAD
  • Jashin J. Wu, MD, FAAD
  • Kelly M. Cordoro, MD, FAAD
  • Kenneth B. Gordon, MD, FAAD
  • Mary M. Tomayko, MD, PhD, FAAD